UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): November 27,
2017
AZURRX BIOPHARMA, INC.
|
|
|
|
|
Delaware
|
001-37853
|
46-4993860
|
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, New York
|
11226
|
|
|
(Address
of principal executive
offices)
|
(Zip
Code)
|
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [
]
Item
5.07
Submission of Matters to a Vote of Security Holders.
On
November 28, 2017, AzurRx BioPharma, Inc. (the “Company”) held its annual meeting
of stockholders (the “Annual
Meeting”). The matters voted upon at the Annual
Meeting and the results of the voting are set forth
below.
Proposal No. 1- Election of Directors
|
|
|
For
|
|
|
Withheld
|
|
Not
Voted
|
|
Johan
(Thijs) Spoor
|
|
6,339,973
|
|
|
77,209
|
|
1,038,377
|
|
Maged
Shenouda
|
|
6,339,973
|
|
|
77,209
|
|
1,038,377
|
|
Edward
J. Borkowski
|
|
5,012,118
|
|
|
1,405,064
|
|
1,038,377
|
|
Alastair
Riddell
|
|
6,339,973
|
|
|
77,209
|
|
1,038,377
|
|
Charles
J. Casamento
|
|
6,339,973
|
|
|
77,209
|
|
1,038,377
|
|
Vern
Lee Schramm, PhD.
|
|
6,339,973
|
|
|
77,209
|
|
1,038,377
|
The
Company’s Directors are elected by a plurality of the votes
cast. Accordingly, each of the nominees named above was elected to
serve on the Company’s Board of Directors until the 2018
annual meeting of stockholders, or until their successors are
elected and qualified.
Proposal No. 2- Ratification of the Appointment of Mazars USA LLP
as the Company’s Independent Auditors for the Fiscal Year
Ending December 31, 2017.
|
For
|
|
Against
|
|
Abstain
|
|
|
7,419,757
|
|
2,968
|
|
32,834
|
|
The vote required to approve this proposal was the
affirmative vote of a majority of the votes cast at the Annual
Meeting. Accordingly, stockholders ratified the appointment
of Mazars USA LLP,
formerly WeiserMazars, as the
Company’s registered public accounting firm auditors for the
fiscal year ending December 31, 2017.
For
more information about the foregoing proposals, please review the
Company’s definitive proxy statement, filed with the
Securities and Exchange Commission on October 20,
2017.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AzurRx BioPharma, Inc.
|
Date: December
1, 2017
|
By:
|
/s/ Johan M.
Spoor
|
|
|
|
|
|
|
Name: Johan M. Spoor
|
|
|
|
Title: Chief Executive Officer
|
|